you are here: Home News Remdesivir

Remdesivir

'Soaring demand' of remdesivir, oxygen during 2nd wave of COVID-19: MHA
COVID-19 treatments for better protection against future variants identified
As COVID-19 cases rise in Maharashtra, doctors say most patients have mild symptoms and fast recovery
India makes COVID-19 treatment drug Remdesivir 'freely exportable'
New antiviral drug combo highly effective against COVID-19: Study
Economic Survey 2022| Govt initiative led to up to 89% fall in prices of key Covid devices
Remdesivir to be used in patients with moderate to severe COVID-19: Health ministry
Covid-19 Third Wave Preparations: 50 lakh Remdeivir in stock, 293 New Functional O2 Plants, 20 Lakh Beds
Drug firms seek free export of Remdesivir as weak demand inflates inventories
COVID-19 update | Poor as well as multi-millionaire of 18 years, above to get free jabs: Centre to Supreme Court
COVID-19 | Centre lifts ban on Remdesivir export, allows overseas sale sans authorisation
Sun Pharma: Traction in speciality likely to sustain
COVID-19: Centre discontinues remdesivir allocation to states, says supply is more than demand
Those indulging in black marketing of Remdesivir being booked under NSA: Yogi Adityanath
Cipla — While COVID scope continues, watch out for FY23
Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term
Lupin: Focus on inhalation and bio-similars to aid margins in medium term
Dr Reddy's signs licensing pact with Eli Lilly to produce COVID-19 treatment drug Baricitinib
Cipla, Jubilant to face action if they fail to fulfill supply obligation of Remdesivir within 24 hours: Karnataka govt
Remdesivir marketing companies to supply 53 lakh vials for April 21-May 16 period to states/ UTs: Govt
Eli Lilly India chief says company in talks with generic firms here on royalty free voluntary licensing of COVID-19 drug Baricitinib
COVID-19 second wave | Two flights carrying aid to India delayed till May 5, says US Department of Defense
COVID-19: As govt cuts GST, a look at duties on certain imported items, more clarity awaited on others
COVID-19: Supreme Court asks Centre to procure licence for generic version of Remdesivir
Syngene: Heavy investment phase makes it a long-term play

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Remdesivir

'Soaring demand' of remdesivir, oxygen during 2nd wave of COVID-19: MHA

COVID-19 treatments for better protection against future variants identified

As COVID-19 cases rise in Maharashtra, doctors say most patients have mild symptoms and fast recovery

India makes COVID-19 treatment drug Remdesivir 'freely exportable'

New antiviral drug combo highly effective against COVID-19: Study

Economic Survey 2022| Govt initiative led to up to 89% fall in prices of key Covid devices

Remdesivir to be used in patients with moderate to severe COVID-19: Health ministry

Covid-19 Third Wave Preparations: 50 lakh Remdeivir in stock, 293 New Functional O2 Plants, 20 Lakh Beds

Drug firms seek free export of Remdesivir as weak demand inflates inventories

COVID-19 update | Poor as well as multi-millionaire of 18 years, above to get free jabs: Centre to Supreme Court

COVID-19 | Centre lifts ban on Remdesivir export, allows overseas sale sans authorisation

Sun Pharma: Traction in speciality likely to sustain

COVID-19: Centre discontinues remdesivir allocation to states, says supply is more than demand

Those indulging in black marketing of Remdesivir being booked under NSA: Yogi Adityanath

Cipla — While COVID scope continues, watch out for FY23

Ideas for profit | Lupin: Focus on inhalation & biosimilars to aid margins in medium term

Lupin: Focus on inhalation and bio-similars to aid margins in medium term

Dr Reddy's signs licensing pact with Eli Lilly to produce COVID-19 treatment drug Baricitinib

Cipla, Jubilant to face action if they fail to fulfill supply obligation of Remdesivir within 24 hours: Karnataka govt

Remdesivir marketing companies to supply 53 lakh vials for April 21-May 16 period to states/ UTs: Govt

Eli Lilly India chief says company in talks with generic firms here on royalty free voluntary licensing of COVID-19 drug Baricitinib

COVID-19 second wave | Two flights carrying aid to India delayed till May 5, says US Department of Defense

COVID-19: As govt cuts GST, a look at duties on certain imported items, more clarity awaited on others

COVID-19: Supreme Court asks Centre to procure licence for generic version of Remdesivir

Syngene: Heavy investment phase makes it a long-term play